Business Description
Spero Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US84833T1034
Description
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 12.87 | |||||
| Equity-to-Asset | 0.54 | |||||
| Debt-to-Equity | 0.06 | |||||
| Debt-to-EBITDA | 0.28 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | -1.58 | |||||
| Beneish M-Score | 11.02 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 433.9 | |||||
| 3-Year FCF Growth Rate | 45.5 | |||||
| 3-Year Book Growth Rate | -23.5 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | -39.15 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 54.98 | |||||
| 9-Day RSI | 52.78 | |||||
| 14-Day RSI | 51.69 | |||||
| 6-1 Month Momentum % | -22.93 | |||||
| 12-1 Month Momentum % | 4.43 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.68 | |||||
| Quick Ratio | 2.68 | |||||
| Cash Ratio | 1.39 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -21.9 | |||||
| Shareholder Yield % | 1.61 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | 19.79 | |||||
| Net Margin % | 16.56 | |||||
| FCF Margin % | -13.45 | |||||
| ROE % | 22.26 | |||||
| ROA % | 12.36 | |||||
| ROIC % | 31.42 | |||||
| 3-Year ROIIC % | 125.07 | |||||
| ROC (Joel Greenblatt) % | 418.72 | |||||
| ROCE % | 16.28 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 3.79 | |||||
| PE Ratio without NRI | 3.07 | |||||
| PS Ratio | 0.66 | |||||
| PB Ratio | 0.87 | |||||
| Price-to-Tangible-Book | 0.87 | |||||
| EV-to-EBIT | 0.63 | |||||
| EV-to-EBITDA | 0.63 | |||||
| EV-to-Revenue | 0.11 | |||||
| EV-to-Forward-Revenue | 0.2 | |||||
| EV-to-FCF | -0.77 | |||||
| Price-to-Graham-Number | 0.34 | |||||
| Price-to-Net-Current-Asset-Value | 1.32 | |||||
| Earnings Yield (Greenblatt) % | 158.73 | |||||
| FCF Yield % | -20.63 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers